To investigate the molecular pathology in acute intermittent porphyria (AIP), the nature of the defective porphobilinogen (PBG)-deaminase was determined in erythrocyte lysates from 165 AIP heterozygotes from 92 unrelated families representing 20 different ethnic or demographic groups. Immunologic and physicokinetic studies revealed the occurrence of four classes of PBG-deaminase mutations. In the majority of families studied, the amount of immunoreactive enzyme protein corresponded to the amount of enzymatic activity, indicating the absence of cross-reacting immunologic material (CRIM) produced by the mutant allele. In 78 of these CRIM-negative families (designated type 1), the affected heterozygotes had half-normal PBG-deaminase activity. In three families (designated CRIMnegative type 2), symptomatic patients had increased urinary excretion of deltaaminolevulinic acid and PBG, and normal levels of erythrocyte PBG-deaminase activity. In contrast, noncatalytic, immunoreactive protein was expressed in heterozygotes from 11 families, about one-eighth of those studied, consistent with mutations in the structural gene for PBG-deaminase. Two types of CRIM-positive mutations were identified: the type 1 mutation had a CRIM/activity ratio of approximately 1.7 and a crossedimmunoelectrophoretic profile in which all the enzyme intermediates were increased, with the B or monopyrrole-enzyme intermediate predominant (B greater than A much greater than C congruent to D greater than E). The mutation altered both the kinetic and stability properties of the noncatalytic immunoreactive enzyme protein. The second CRIM-positive mutation, type […] 
inborn error of heme biosynthesis that results from the halfnormal activity of porphobilinogen deaminase (PBG-deaminase; EC 4.3.1.8) (1) (2) (3) (4) . Clinical expression of the disease is highly variable, determined in part by environmental, metabolic, and hormonal factors that induce hepatic 6-aminolevulinic acid synthase activity and the subsequent increased production of heme precursors (5) (6) (7) . Although the disease is clinically latent in many heterozygous individuals, those who are symptomatic usually have elevated levels of urinary PBG and its precursor, 5-aminolevulinic acid (ALA), particularly during acute attacks. Most affected individuals can be diagnosed enzymatically (i.e., decreased erythrocyte PBG-deaminase activity); however, kindreds have been described recently in which symptomatic patients have normal levels of the erythrocyte PBG-deaminase activity and markedly elevated urinary PBG and ALA levels (8, 9) . PBG-deaminase is encoded by a structural gene located on the distal portion of the long arm of chromosome 11 (I lq23 -1 lqter) (10) . The erythrocyte enzyme has been purified to homogeneity and its physicokinetic properties have been characterized (1 1) . The active enzyme protein is a monomer (Mr -42,000) that catalyzes the sequential head to tail condensation of four molecules of PBG to form hydroxymethylbilane, a linear tetrapyrrole that nonenzymatically cyclizes to uroporphyrinogen I. Hydroxymethylbilane is synthesized by a reaction mechanism involving the stepwise formation of stable enzymesubstrate intermediates (11) (12) (13) . Five enzyme intermediates, A-E, have been identified by chromatographic and electrophoretic techniques, the A form being the free enzyme and the B, C, D, and E forms representing the mono-, di-, tri-, and tetrapyrrole substrate-enzyme intermediates, respectively (1 1, 14) .
The overall Km for the reaction was 6 gsM and kinetic studies indicated that the C intermediate, the dipyrrole-enzyme complex, was either the most stable intermediate or the ratelimiting step in the conversion of the monopyrrole to the tetrapyrrole (1 1, 14) .
In a previous communication, we reported the first immunologic characterization of the enzymatic defect in unrelated heterozygotes with AIP (14) . Monospecific anti-human PBGdeaminase antibodies, which uniformly recognized each of the enzyme intermediates, were used to quantitate and characterize the amount of PBG-deaminase cross-reacting immunologic material (CRIM) in erythrocyte lysates from 32 heterozygous individuals of 22 unrelated AIP families. Two classes of mutations were identified. In 21 of the AIP families, the amount of enzyme protein was directly proportional to the amount of enzymatic activity (i.e., the CRIM/activity ratio was _1.0); these mutations were classified CRIM-negative. In seven affected members from a family of Basque ancestry, the PBG-deaminase mutation was CRIM-positive; the CRIM/ activity ratio of -1.65 indicated the presence of immunoreactive, noncatalytic enzyme produced by the mutant allele. Although only 1 of the 22 AIP families had a CRIM-positive mutation, this finding provided evidence for heterogeneity of the genetic defect in AIP.
In this communication, we report the immunologic and physicokinetic properties of erythrocyte PBG-deaminase in 165 AIP heterozygotes from 92 unrelated families representing 20 different ethnic or demographic backgrounds. Four classes of mutations were identified: two were CRIM-negative and two were CRIM-positive. The CRIM-negative mutations were divided into two types based on the level of erythrocyte PBGdeaminase activity. The majority of CRIM-negative families, designated type 1, had half-normal activity, whereas several CRIM-negative families, including a large Finnish kindred (8) Assays PBG-deaminase assay. Enzymatic activity was determined by the quantitation of uroporphyrin fluorescence as previously described (15) . One unit of enzymatic activity equaled that amount of enzyme that formed I nmol of uroporphyrin per h at 37GC.
Protein assay. Protein concentrations were determined by the fluorescamine procedure as previously described (17) .
Kinetic, heat denaturation, and protease stability studies For kinetic studies, 50 Ml of erythrocyte lysate was incubated in the standard assay with the final substrate concentration ranging from 0 to 50 MM. The Km values were determined from Lineweaver-Burk plots.
To determine the effect of heat denaturation on erythrocyte PBGdeaminase activity, 500 l aliquots of the lysates, which were equalized for activity, were placed in screw-capped vials and incubated at 650 or 70GC for 2 h, and then cooled to 0°C. After centrifugation at 10,000 g for 10 min to remove precipitated proteins, 50 Ml of the supernatant was removed and immediately assayed for PBG-deaminase activity.
To study the effect of trypsin and pronase on PBG-deaminase activity, erythrocyte lysates were equalized for protein concentration (to 80 mg/ml by dilution with lysis buffer). Aliquots (40 M41) of each lysate were placed at 0°C, then 10 Ml of lysis buffer containing 125 Mg/ml of pronase or 0.0625 ,g/ml of trypsin was added to give a final protease concentration of 25.0 Ag/ml or 0.0125 Ag/ml, respectively.
The reaction mixtures were preincubated for 0-60 min at 37°C, after which time 500 Ml of 0.1 M Tris-HCl buffer, pH 8.1, containing 0.1 mM DTT, and 200 Ml of 0.5 mM PBG were added immediately and the PBG-deaminase activity determined as described above.
Immunologic studies
Characterization ofanti-PBG-deaminase. Anti-human PBG-deaminase was raised in New Zealand rabbits immunized with the homogeneous A intermediate and the IgG fraction was purified as previously described (14) . This antibody preparation was shown to be specific for purified human PBG-deaminase (or the human enzyme in erythrocyte lysates or murine erythroleukemia-human fibroblast somatic cell hybrids) by Ouchterlony double-immunodiffusion and competitive immunoprecipitation studies (10, 14) . Ouchterlony immunodiffusion gels showed a single arc of identity between the homogeneous enzyme and that in human erythrocyte lysates or liver homogenate supernatants when stained for protein and activity using PBG as substrate (Desnick, R. J., et al., unpublished results).
Immunotitration of anti-human PBG-deaminase. Homogeneous PBG-deaminase intermediate A (40 ng of enzyme diluted with BSA to 50 Ml; final protein concentration of 40 mg/ml) and 50 Ml of rabbit anti-PBG-deaminase IgG (in serial dilutions) were mixed and incubated at 37°C. After 30 min, 50 Ml of goat anti-rabbit IgG was added and the mixture was incubated at 37°C for 30 min. To insure quantitative precipitation of the anti-PBG-deaminase antibodies, the samples were left at 4°C overnight. The mixtures were then centrifuged at 4,000 g for 15 min and the activity in the supernatant was determined by the After electrophoresis, the gel was thoroughly washed in 0.9% NaCI for 10-12 h with several changes and then the antibody containing part of the gel was overlayed with 300 Ml of peroxidase-conjugated goat anti-rabbit IgG which had been diluted 1: 2 with 0.9% NaCl. The plate was incubated at room temperature in a moist chamber to prevent drying. After another overnight wash with 0.9% NaCl, the gel was stained for peroxidase with 50 ml of 0.1 M Tris-HCI buffer, pH 7.6, containing 25 mg of diaminobenzidine tetrahydrochloride and 0.15 ml of 3% hydrogen peroxide. After staining for 10-20 min at room temperature, the rockets were visualized by using an indirect light source, and the gel was photographed and stored in 0.9% NaCl at 4°C. Isoelectric focusing and crossed-immunoelectrophoresis. Isoelectric focusing of the PBG-deaminase intermediates was performed on horizontal agarose slab gels using the Pharmacia system according to the manufacturer's instructions. Gels were prepared by heating a mixture of 0.3 g of AgaroseIEF 3.6 g of sorbitol, and 27 ml of distilled water in a boiling water bath. After cooling to 75°C, 1.9 ml of pH 5-8 Pharmalyte ampholines were added. The mixture was then poured into a horizontal casting frame (11.4 X 22.5 cm; with Gelbond film backing), which had been preheated to about 60°C using a portable hairdryer. Gels were allowed to harden at least 1 h at 4°C or stored overnight at 4°C in a moist chamber. Prior to isoelectric focusing, erythrocyte lysates were heated at 60°C for 1 h and centrifuged at 10,000 g for 20 min, and then aliquots of the supernatants (50-100 Ml) were pipetted onto Whatman No. 17 paper strips (Whatman Laboratory Products, Inc., Clifton, NJ) and placed 1 cm from the cathode. The cathode contained 1.0 M NaOH and the anode 0.05 M H2SO4. Focusing was carried out for 2.5 h at 10 W (constant power) at 4°C. The filter paper strips were removed after the hemoglobin had migrated about 1 cm from the origin. After focusing, the pH gradient was determined by removing a 0.5-cm gel strip, cutting it into 1-cm pieces which were soaked in distilled H20, and then the pH values of the leached ampholytes were measured. For visualization of activity bands, the gel was overlaid with Whatman No. 3MM filter paper saturated with 0.5 mM PBG, covered with polyvinylchloride film, and incubated at 37°C for 90 min in the dark. The overlay was removed and the gel was exposed to ultraviolet light for 10 min to oxidize the uroporphyrinogen to uroporphyrin, and the red fluorescent bands of PBG-deaminase activity were rapidly photographed under ultraviolet light with Polaroid Type 58 film (Polaroid Corp., Cambridge, MA) using a Wratten No. 4 filter.
Crossed-immunoelectrophoresis of the separated PBG-deaminase intermediates was performed by placing an unstained lane from the focusing gel at the cathodal end of a rocket immunoelectrophoresis plate. The remainder of the plate was filled with 8 ml of 1% agarose containing 40 Ml of anti-PBG-deaminase IgG and rocket immunoelectrophoresis was carried out as described above. Crossed-immunoelectrophoretic gels were stained for protein with Coomassie Brilliant Blue R-250 as previously described (14) .
Results
Immunologic identification ofPBG-deaminase mutant classes.
The PBG-deaminase CRIM status was determined in 165 AIP heterozygotes from 92 unrelated families representing at least 20 different ethnic or demographic backgrounds (Table I) . For these studies, equal amounts of erythrocyte PBG-deaminase activity from each AIP heterozygote and normal individuals were subjected to rocket immunoelectrophoresis. AIP heterozygotes whose rocket peak heights were essentially identical to (Fig. 2) . The identity of their immunotitration curves confirmed the rocket immunoelectrophoretic studies that indicated the absence of noncatalytic enzyme protein in either type of CRIM-negative heterozygote.
In that the amount of CRIM detected by either technique corresponded to the amount of erythrocyte activity used, the CRIM/activity ratios for the CRIM-negative type 1 and 2 heterozygotes and normal individuals were 1.0.
In contrast, immunotitration of identical amounts of activity from the CRIM-positive type I and 2 heterozygotes required antibody dilutions of 1:1 16 and 1:35 to precipitate 50% of the supernatant activities, respectively (Fig. 2) . The antibody dilutions required to precipitate 50% of the activity from 1:1 i.S Fig.  3 , the rocket peak heights for 7 and 10 mU of PBG-deaminase activity in the CRIM-positive type 2 erythrocytes were essentially equal to those obtained for 40 and 56 mU of normal lysate activity, respectively. Thus, the CRIM/activity ratio determined by rocket immunoelectrophoresis was -5.7, consistent with the values for the CRIM-positive type 2 heterozygotes obtained by immunotitration.
Characterization of the PBG-deaminase intermediates in the AIP mutant classes. Crossed-immunoelectrophoresis of erythrocyte PBG-deaminase provided further information concerning the nature of the enzymatic defect in the four AIP mutant classes. For these studies, PBG-deaminase in erythrocyte lysates was first subjected to isoelectric focusing in agarose gels to separate the enzyme intermediates. Five major PBG-deaminase activity bands were observed in normal and CRIMpositive type 1 and 2 lysates (Fig. 4) (14) , and equal activities of the A, B, C, and D forms were subjected to rocket immunoelectrophoresis. As shown in Fig. 5 14) . Kinetic, heat denaturation, and protease stability studies. The physicokinetic properties of the PBG-deaminase in erythrocyte lysates from normal individuals and each of the AIP mutant classes are summarized in Table II . The Km values calculated from Lineweaver-Burk plots were essentially the same (-6 gM) from all sources. However, heat denaturation and protease digestion studies revealed differences among the AIP mutant classes. When the lysates were heat denatured at 650 and 70°C, the CRIM-positive type 2 enzyme was most stable and was slightly activated at 65°C. The CRIM-positive type 1 and CRIM-negative type 1 activities had mean heat inactivation values that were similar to those of the normal enzyme. Interestingly, the CRIM-negative type 2 activity was less stable than the normal enzyme after heat treatment at 65°C. When equal amounts of erythrocyte protein from each of the mutant classes were subjected to pronase or trypsin digestion, the activities of the CRIM-positive type 1, both CRIM-negative type 1 and 2 heterozygotes, and normal individuals were equally digested by either protease. In contrast, the CRIM-positive type 2 activity was more stable to pronase digestion and appeared slightly more stable to trypsin degradation. Rocket immunoelectrophoresis of equal activities of each mutant class did not reveal any differences in the peak height of the enzyme before or after pronase or trypsin digestion (data not shown), suggesting that the partially degraded enzyme proteins lost activity, but fully retained their antigenic properties.
Discussion
Four major mutant classes were identified by immunologic and physicokinetic studies of PBG-deaminase in erythrocytes from unrelated AIP heterozygotes with this dominantly inherited, inborn error of metabolism. Two of these mutant classes had been defined previously by immunologic studies of heterozygotes from 22 unrelated AIP families (14) . By using monospecific antibodies to quantitate immunoreactive enzyme protein, the heterozygotes from all but one of these families were found to be CRIM-negative (CRIM/activity ratio -1.0), (11) (12) (13) . Previously, a model was proposed (Fig. 9) , which predicted the different types of mutations which might be revealed by immunologic characterization of the PBG-deaminase intermediates in CRIMpositive heterozygotes (14) . This model assumes that the normal enzyme has two binding sites for PBG and one active site (18) , with the normal reaction mechanism involving the stepwise formation of the mono-, di-, tri-, and tetrapyrroles by the enzyme-substrate intermediates, A-E. Mutations that render substrate-binding site 1 
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Immunologic characterization of the CRIM-positive type 1 mutation revealed that each of the enzyme intermediates had elevated levels of cross-reactive material and the noncatalytic B enzyme-substrate intermediate was present in the greatest amount as previously described (14) . These findings best fit the model for a Km mutation with a markedly altered, but functional, active site and an altered substrate-binding site 2 (Fig. 9) . In addition, the immunoreactive gene product produced by the mutant allele was somewhat unstable, because the CRIM/activity ratio was 1.7, whereas a totally stable mutant protein would have had a CRIM/activity ratio of 2.0 in the heterozygous lysate.
In marked contrast, the CRIM-positive type 2 mutants had a CRIM/activity ratio of -5.7 (range 4.9-6.0), an unexpected finding, and a crossed-immunoelectrophoretic profile in which the immunoreactive B, C, D, and E enzyme-substrate intermediates were markedly elevated, while the A intermediate, the free enzyme, was only slightly increased. These findings best fit the model, which predicted increased binding or defective release of the bound substrate molecules (Fig 9) The CRIM-negative type 2 mutation was differentiated from the CRIM-negative type 1 mutation by the fact that the level of erythrocyte PBG-deaminase activity in these individuals was within the normal range. The normal erythrocyte PBGdeaminase levels in these individuals did not result from elevated reticulocyte counts, nor were they due to the biologic range in the expression of a single normal allele (e.g., high heterozygote level), since the activity ratios of erythrocyte PBG-deaminase to 5-aminolevulinate dehydratase and uroporphyrinogen III cosynthase were normal (Desnick, R. J., unpublished observations). Several hypotheses have been advanced to account for the normal erythrocyte PBG-deaminase activities in these symptomatic patients. It has been suggested that these AIP heterozygotes have half-normal hepatic PBG-deaminase activities and normal erythrocyte levels (8) . This hypothesis requires the presence of two structural genes encoding hematopoietic (e.g., erythrocytic) and nonhematopoietic (e.g., hepatic) isozymes or a regulatory mechanism which controls either the tissue specific expression of a single structural gene or the differential expression of hematopoietic and nonhematopoietic isozymes. Support for this concept will await determination of the hepatic activity in these patients. However, the fact that human PBG-deaminase has been assigned to a single, narrow, chromosomal location (10) and the finding that monospecific antibodies against the purified erythrocyte enzyme form a single line of identity with partially purified hepatic and erythrocytic PBG-deaminase activities, argue against this hypothesis (Ostasiewicz, L. T., and R. J. Desnick, unpublished results). Nevertheless, it is possible that two or more structural genes are present as a gene family in the same chromosomal region, analogous to the fl-globin gene complex (22) , and that the antierythrocyte PBG-deaminase antibodies did not recognize unique determinants of a hepatic isozyme. Another explanation which also may depend on the occurrence of separate genes encoding hepatic and erythrocytic enzymes, is the suggestion that the defect in AIP results from a regulatory gene mutation (7, 23) . Such a mutation could result in normal hematopoietic, but half-normal hepatic gene expression.
Finally, one could account for the rare individuals with normal erythrocyte activity by the segregation of a variant allele with high normal activity (i.e., a hypermorph). It is well known that there is a large range (about threefold) in normal erythrocytic PBG-deaminase levels and that this variation is genetically determined (24, 25) . The occurrence of two codominant PBG-deaminase alleles was hypothesized recently to account for the distribution of the erythrocyte activities in over 200 normal individuals (26) . For the two-allele model, the mean activities for the trimodal distributions were -130, 170, and 220 pmol/30 min mg protein, respectively. If an individual inherited such a hypermorphic allele and an AIP mutant allele, the level of erythrocyte PBG-deaminase activity may be within the normal range (but the nonhematopoietic activities could be half-normal). Symptomatic individuals in such a family have been described (27) ; normal individuals with the hypermorphic allele had high normal activities of erythrocyte PBG-deaminase, whereas symptomatic heterozygous individuals, who had the hypermorphic allele and a mutant AIP allele, had erythrocyte activities in the normal range. However, characterization of the erythrocyte enzyme in six asymptomatic, apparently normal members of the large Finnish CRIM-negative type 2 family did not reveal activity levels consistent with the presence of a hypermorphic allele. Therefore, it is likely that insight into the precise nature of the defect in these CRIM-negative type 2 heterozygotes will be revealed by molecular studies of their PBG-deaminase genes.
In summary, immunologic and biochemical characterization of the enzymatic defect in a large series of unrelated AIP families identified four classes of PBG-deaminase mutations. At the molecular level, the two CRIM-positive mutations most likely result from single base substitutions in the exons of the structural gene. The CRIM-negative mutations may represent mutations which (a) markedly alter enzyme stability or antigenicity, (b) result in early chain termination, or (c) alter mRNA transcription or processing. The classification of these mutations should facilitate the initial selection of appropriate candidates for future molecular genetic analyses, analogous to the characterization of the genetic defects in the human thalassemias (22) .
